Informed Prostate Cancer Patient Support

Prostate Cancer Treatment Associated With Long-Term Complications | MedPage Today medpagetoday.com Prostate Cancer Treatment Associated With Long-Term Complications Staff Writer, MedPage Today 5–7 minutes Urology > Prostate Cancer — Researchers say inadequate understanding of risks may lead patients to regret treatment decisions by Mike Bassett , November 7, 2024 Even accounting for age-related symptoms and disease, treatment of prostate cancer came with higher rates of complications associated with worse quality of life and new health risks, a cohort study showed. At 12 years, the...

Where your Metastases Are Makes a Difference You Have Choices - Genes and Biomarkers Help Select a Path Understanding PARP Inhibitors: A New Option for Advanced Prostate Cancer Unlocking the Power of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer - Unlocking the Power of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer.pdf   -------------------------------------------------------------------- When I learned my prostate cancer had become resistant to hormone therapy, (my PSA was going up even though I was on ADT with enzalutamide or abiraterone) I thought this meant I had run out of treatment options, but I found that the clinical technology has been rapidly developing. "My doctor mentioned something called PARP inhibitors, but I didn't understand what they were or if they were right for me," I recall. My experience is common among men with metastatic castration-resistant prostate cancer (mCRPC). Here's what you need to know sho...

Analysis of transcriptomic data from a cohort of CRPC patients 24 categorized based on high and low PRKCI expression revealed the upregulation of the histone methyltransferase EZH2 in PRKCI- low tumors along with increased levels of neuroendocrine markers such as chromogranin A ( CHGA ) or synaptophysin ( SYP ), and the reduced expression of AR and AR-dependent genes, including KLK2 and KLK3 Scientists Discover New Treatment Strategy for Xtandi-Resistant Prostate Cancer Scientists at Weill Cornell Medicine have uncovered a promising new approach to treat prostate cancer that has become resistant to enzalutamide, a common hormone therapy. The research, published in Nature Communications, reveals how targeting protein production in cancer cells could help overcome treatment resistance. The team found that prostate cancer cells lacking a protein called PKCλ/ι become resistant to enzalutamide but are uniquely vulnerable to drugs that block protein synthesis. When researchers ...